Abstract: Sleep disorders are frequently reported in autistic patients. Evidences suggest that increased oxidative stress and reduced antioxidants may play a major role in the pathogenesis of these disorders. Carnosine acts as an antioxidant, antitoxic and neuroprotective agent. The aim of this trial study was to examine the effects of carnosine supplementation on the sleep disorders and severity of autism core symptoms in autistic patients. In this double-blind, randomized clinical trial, 43 autistic patients (31 boys and 12 girls; aged 4 to 16 years) were divided into two groups of carnosine and control that received 500 mg of carnosine and 500 mg of placebo per day for 2 months, respectively. Sleep disorders were measured using Children's Sleep Habits Questionnaires. Gilliam Autism Rating Scale 2 was used to assess the effects of carnosine supplementation on the autism severity. Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group. The results suggest that carnosine supplementation could be effective in improving sleep disturbances, in particular sleep duration and parasomnias subscales.
Sleep disorders are any impairment in the quality, timing and amount of sleep which are connected with neurocognitive and psychosocial problems. Interrupted sleep could be associated with overall health, quality of life and contribute to considerable impairments in daytime functioning and cognitive functioning which includes attention, learning and memory. Difficulty in falling asleep, excessive daytime naps, night wakings, anxiety and abnormal movements during sleep are some of the signs and symptoms of sleep disorders [1] . To date, little is known about the origin of sleep disorders, but it is speculated that the following could be the cause: autistic behaviours, panic, anxiety and melatonin abnormal levels [2] .
Autism spectrum disorder (ASD) is a long-term, complex neurodevelopmental condition defined by stereotyped behaviours or interests and impairment in social communication [3] . Considerably, the frequency of ASD has increased in the past years. In the year 2000, ASD frequency was 6.7 per 1000 in 8-year-old children and it increased to 14.7 per 1000 in 2010 [4] and also increased from 1.25 to 2.24% from 2011 to 2014, in children of ages 3-17 years according to National Health Interview Survey [5] . ASD is accompanied by coexistence of various clinical features, such as intellectual disability, epilepsy, attention-deficit/hyperactivity disorder (ADHD), language disorder, depression, sleep disturbances and gastrointestinal (GI) disorders [6] . Among the wide range of potential clinical disorders, sleep irregularities are more common [7] . According to evidences, sleep difficulty is present in 56 to 68% of autistic children [8] . In our previous study, it was demonstrated that severity of autism significantly and positively related to sleep disorders [9] .
Increasing evidence suggests that elevated oxidative stress and reduced antioxidant levels are related to ASD severity [10] and sleep deprivation [11] [12] [13] . On the other hand, primary results of some clinical trials have reported improved behaviour in autistic individuals who received antioxidant therapy [14] . L-Carnosine is a natural dipeptide which consists of b-alanine and L-histidine concentrated in brain and muscles. Previous studies strongly support the idea that this peptide acts as an antioxidant, antitoxic and neuroprotective agent [15] . Recently, clinical studies have shown that autistic patients have lower circulating carnosine than healthy controls [16] [17] [18] . Therefore, carnosine has been identified as a novel and emerging treatment for ASD [19, 20] . Chez et al. [21] suggested that carnosine supplementation improves some clinical features in autistic children, such as receptive speech, social attention and behaviour.
Concerning the established link between reduced levels of antioxidants and sleep deprivation [11] [12] [13] , carnosine antioxidant properties and existing evidence on reduction in carnosine in autistic patients, the question remains whether carnosine supplementation would improve interrupted sleep and severity of disease in these patients? Therefore, this study was conducted to investigate any possible impact of carnosine supplementation on the sleep disorders and severity of autism core symptoms in autistic children.
Materials and Methods
Study design. This study was a 2-month, double-blind, randomized and placebo-controlled trial carried out in an outpatient clinic affiliated to Tabriz University of Medical Sciences and four private autism treatment centres in the Tabriz city, East Azerbaijan, Iran, from June 2016 to December 2016. The study was approved by the Research Ethics Committee of the University and registered in the Iranian Registry of Clinical Trials (www.irct.ir; IRCT Registration Number: IRCT2016061711689N5). The participants were given a complete study explanation and parents of all the participants gave written informed consent, according to the Ethical Committee guidelines, prior to participation in the study.
Participants. Fifty autistic patients, male or female, aged between 4-16 years with a Diagnostic and Statistical Manual of Mental Disorders -fifth edition [3] diagnosis of autism, made by a specialist clinician, were selected for this study. Eligible participants were autistic patients with sleep disorders who were on a constant medical protocol for at least 2 months before the intervention. The exclusion criteria were consumption of any type of chelator drugs, using any antioxidant supplements during the study period, those following special diets, individuals with other neurological diseases (for instance, epilepsy, cerebral palsy), any types of metabolic disorders, disinclination to start or to continue cooperation and acceptance rate <75%. The participants were randomly divided into carnosine or placebo groups and matched for age and sex based on random block procedure consisting of four individuals per block. To guarantee blindness of the intervention, the supplements were distributed among the participants in conformance with the allocation code. Using Pocock formula, with 95% level of confidence and 80% power, and by considering the total sleep score according to the study of Souders et al. [22] and a drop-out rate of 20%, a minimum sample size of 20 in each group was estimated.
Intervention procedures. Demographic data were collected from participants' parents via face-to-face interview, at the beginning and end of the intervention. Participants in the carnosine group were supplemented with 500 mg capsules of L-carnosine (provided by Nova Nutritions; Scotch Plains, New Jersey) once a day, preferably with lunch meal. Participants in the placebo group were given 500 mg capsules with cornstarch.
Primary outcome of the intervention.
Effect of the carnosine supplementation on sleep disorders. To evaluate the effect of the carnosine treatment on sleep disorders of the participants, Iranian version of Children's Sleep Habits Questionnaire (CSHQ) was used at the beginning and end of the intervention. This tool was previously validated using content validity, and its internal consistency was used at 0.82 Cronbach's a coefficient for the total scale [23] . It is a retrospective sleep screening instrument with 33 items and eight subscales which reflect key sleep scopes identifying the main sleep problems. Sleep-onset delay (e.g. the amount of time it takes a child to fall asleep), sleep duration (e.g. the length of time for which the child sleeps), night wakings (e.g. any waking of the child after falling asleep), sleep-disordered breathing (e.g. whether the child has nocturnal breathing difficulties such as snoring or obstructive sleep apnoea), bedtime resistance (e.g. calling out from or leaving one's room after bedtime), sleep anxiety (feeling of worry, nervousness or unease occurs right before/during sleep), parasomnias (abnormal movements, behaviours, emotions, perceptions and dreams that occur while falling asleep) and daytime sleepiness (e.g. child naps during the day, suddenly falls asleep in the middle of active behaviour). Finally, a total score of 41 points represent a paediatric sleep disorder [24] . Higher scores represent more disturbed sleep. Parents answered to items or questions concerning child's sleep in the last week. The frequency of sleep behaviours was noticed on a 3-point scale as follows: usually (five to seven nights per week), sometimes (two to four nights per week) or rarely (zero to one night per week). Subscale components of the instrument consist of bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night wakings, parasomnia, sleep-disordered breathing and daytime sleepiness.
Effect of the carnosine supplementation on severity of autism. To assess the effect of the carnosine treatment on severity of disease, Gilliam Autism Rating Scale 2 (GARS-2) was used at the beginning and end of the intervention. The GARS is a behaviour checklist that consists of four subscales. It is designed for children and adolescents aged 3-22 years and completed by parents or professionals in about 10 min. Each subscale describes autism behavioural symptoms to consist of stereotyped behaviours, communication, social interaction and developmental disturbances. These subscales' raw scores were turned into standard scores and then combined as an Autism Quotient. By means of Autism Quotient, higher scores indicate greater autistic severity [25] . To adopt Iranian culture, a previously validated Persian version of GARS was used with content validity and internal reliability (Cronbach's a) of 0.89 [26] .
Secondary outcome of the intervention.
Effect of the carnosine supplementation on anthropometric parameters. To assess the effect of the carnosine supplementation on anthropometric parameters, both at the beginning (pre-intervention) and end of the intervention, participants' weight and height were measured using a stadiometer and digital scale combination (SECA, German) and then body mass index (BMI) was calculated by dividing the body-weight (kg) to the height (m) squared. Nutritional status of the children was recognized following the BMI-for-age z-scores based on the World Health Organization references for each sex, separately. Three nutritional status were identified as underweight (≤À2 S.D. Z-scores), normal weight (<À2 and >+2 Z-scores) and overweight or obesity (≥ +2 S.D. Z-score).
Statistical analysis. All statistical analyses were performed using SPSS version 22 (SPSS, Inc. IL, Chicago, USA). Quantitative and qualitative data were expressed as mean (standard deviation) and frequency (per Table 1 . Demographic characteristics of the studied groups at baseline (n = 43). 
Variables

Results
Participants.
Of the 50 autistic participants enrolled, 43 completed the study (carnosine group n = 21, control group n = 22; fig. 1 ). None of the participants reported any adverse effects or symptoms caused by intervention. Some parents complained of irritation and hyperactivity of their children which were offered to consume supplement with supper meal to alleviate the problem.
Demographic data of the participants.
There was no significant difference in demographic characteristics, including age, sex and birth order between the studied groups (table 1) . Risperidone and Ritalin were the major consumed medications among the participants (table 1) .
Anthropometric outcome.
As presented in table 2, at the baseline, there was no significant difference in anthropometric indices between the two groups (p > 0.05) and there was also no difference between the two groups in nutritional status of children (p = 0.77). Some of the children, 71.4% in the carnosine group and 77.3% in the control group were within the normal range of weight (table 1) . According to ANCOVA test adjusted for baseline values, no significant differences were observed for anthropometric outcome between the two groups at the end of the trial (p > 0.05).
Sleep outcome.
Comparison between the two groups showed that there were no significant differences in baseline CSHQ scales (table 3) . After 2 months of supplementation, all scales remained unchanged in the placebo group, whereas daytime sleepiness and total sleep disorders score significantly decreased in the carnosine-supplemented group when compared with the pre-test values (p = 0.022 and p < 0.001, respectively). At the end of intervention, significant reduction was observed in sleep duration, parasomnias and total sleep disorders score in the carnosine-supplemented group when 4 Paired sample t-test. 5 Median (interquartile range); p < 0.05 considered significant for all tests. 6 Mann-Whitney test. 7 Wilcoxon signed rank test.
The bold values representing statistically significant differences between the two groups.
compared with the placebo group (p < 0.05; ANCOVA adjusted for baseline values).
Behavioural outcome (Autism severity).
At the baseline, there was no significant difference in the disease severity between the two groups (table 4) . After 2 months intervention, no significant change was observed in autism severity in both groups, when compared with the baseline values (p > 0.05). Moreover, no significant difference was observed in autism behavioural outcome in the carnosine group when compared with the control group (p > 0.05;
ANCOVA adjusted for baseline values).
Discussion
Increased evidence suggests that neurodevelopmental disorders such as autism are consequences of extreme vulnerability of the brain to oxidative stress, particularly during the early stage of development. Recent reports have shown increased levels of oxidative stress markers in individuals with disturbed sleep [11] [12] [13] , and also in autistic patients confirming its possible role in the pathogenesis of sleep disturbances as well as autism [14] . As carnosine offers neuroprotective and antioxidative capacity, targeting oxidative stress through its supplementation provides an exciting opportunity to improve sleep irregularities in autism. The results of this study suggest that supplementation with carnosine can significantly improve sleep disorders in autistic children. It was observed that carnosine supplementation significantly reduced sleep disturbances by 7.59%. Previously, various studies have been conducted to evaluate oxidative stress as markers of sleep deprivation. Lungato et al. [11] in an animal model study reported altered antioxidants gene expression and activity in splenocytes of sleep-deprived mice. Everson et al. [12] showed that reduced antioxidants level and activity are associated with sleep deprivation and recovery sleep regulated antioxidants level and increased their activity. Villafuerte et al. [13] suggested that sleep deprivation is associated with oxidative stress and sleep has an important antioxidant function. Chen et al. [27] suggested that correcting disorganized sleep patterns through cognitive-behavioural therapy reduced inflammation and oxidative stress in haemodialysis patients. Taken all together, it is possible that oxidative stress contributes to induction of sleep disturbances. With regard to our results, perhaps, carnosine prevents sleep impairment in autistic children via its powerful antioxidant activity.
In line with the findings of the current study, future studies are needed to reveal the underlying mechanisms in testing antioxidant and oxidative stress levels in autistic children with sleep problems treated with carnosine and investigate the aforementioned cause and effect relationship.
The results of the present study showed that carnosine supplementation had no effect on autism severity which was in disagreement with the results of a study on carnosine supplementation on autistic children by Chez et al. [21] . They suggested that carnosine supplementation improved receptive speech, social attention and behaviour. Although the present study is similar with the study regarding age of the participants and supplementation period, it seems that the significantly improved outcome in the Chez study might be as a result of higher dose of carnosine (800 mg versus 500 mg). 4 Paired sample t-test. 5 Median (interquartile range); p < 0.05 considered significant for all tests. 6 Mann-Whitney test. 7 Wilcoxon signed rank test.
Conclusion
Autism spectrum disorder is an acute, life-lasting disorder with serious psychological and financial consequences. Based on the parameters measured in this study, oral carnosine supplementation may safely improve sleep disorders in autistic children. Further investigations are needed to critically validate the efficacy of carnosine on sleep disturbances and show its mechanisms. It is recommended that the correlation between the clinical response of carnosine and the biochemical changes in autistic patients be perused.
Limitations.
In this study, some considerations should be taken into account. Firstly, it seems that a larger sample size and a higher power for some variables would be of help to reach a level of statistical significance. In addition, the heterogeneity of the participants regarding age restricted the study results. Finally, parents' limited education and lack of awareness about autistic behaviours may have affected the studied measures.
Generalizability.
It is important to appreciate that, to date, this is the first clinical trial undertaken to examine the effects of carnosine on sleep disorders in patients with ASD. Although the recruited population was relatively small and heterogeneous, all the patients included had sleep disorders that is helping to maximize the generalizability of the results. Therefore, it is possible to generalize the findings of the study to populations that are more proximally similar to our study. However, further evaluations with larger participants are encouraged to confirm the results.
